Cargando…

Can We Use Urinary Cytokine/Chemokine Analysis in Discriminating Ulcer-Type Interstitial Cystitis/Bladder Pain Syndrome?

Purpose: Interstitial cystitis/bladder pain syndrome (IC/BPS) has ulcer (HIC) and non-ulcer subtypes. Differentiation of these two subtypes could only be based by cystoscopy. This study analyzed the urinary cytokines and chemokines among IC/BPS subtypes and controls for discriminating HIC from non-H...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Yuan-Hong, Jhang, Jia-Fong, Kuo, Hann-Chorng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9139888/ https://www.ncbi.nlm.nih.gov/pubmed/35626252 http://dx.doi.org/10.3390/diagnostics12051093

Ejemplares similares

Use of Urinary Cytokine and Chemokine Levels for Identifying Bladder Conditions and Predicting Treatment Outcomes in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Yu, Wan-Ru, et al.
Publicado: (2022)

Use of Urinary Biomarkers in Discriminating Interstitial Cystitis/Bladder Pain Syndrome from Male Lower Urinary Tract Dysfunctions
por: Yu, Wan-Ru, et al.
Publicado: (2023)

Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease
por: Jhang, Jia-Fong, et al.
Publicado: (2016)

Usefulness of Urinary Biomarkers for Assessing Bladder Condition and Histopathology in Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Current Understanding of the Pathophysiology and Novel Treatments of Interstitial Cystitis/Bladder Pain Syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

The clinical application of intravesical botulinum toxin A injection in patients with overactive bladder and interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Sensory Receptor, Inflammatory, and Apoptotic Protein Expression in the Bladder Urothelium of Patients with Different Subtypes of Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2023)

Urine Oxidative Stress Biomarkers as Novel Biomarkers in Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Discriminating Different Bladder and Bladder Outlet Dysfunctions by Urinary Biomarkers in Women with Frequency–Urgency Syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2023)

Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2016)

Dysregulation of bladder corticotropin-releasing hormone receptor in the pathogenesis of human interstitial cystitis/bladder pain syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2019)

Changes in the Ultrastructure of the Bladder Urothelium in Patients with Interstitial Cystitis after Intravesical Injections of Platelet-Rich Plasma
por: Lee, Yu-Khun, et al.
Publicado: (2022)

Treatment Outcomes of Intravesical Botulinum Toxin A Injections on Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Yu, Wan-Ru, et al.
Publicado: (2022)

Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition
por: Jhang, Jia-Fong, et al.
Publicado: (2018)

Possible Association between Bladder Wall Morphological Changes on Computed Tomography and Bladder-Centered Interstitial Cystitis/Bladder Pain Syndrome
por: Jhang, Jia-Fong, et al.
Publicado: (2021)

Urine biomarkers in ESSIC type 2 interstitial cystitis/bladder pain syndrome and overactive bladder with developing a novel diagnostic algorithm
por: Jiang, Yuan-Hong, et al.
Publicado: (2021)

Difference in electron microscopic findings among interstitial cystitis/bladder pain syndrome with distinct clinical and cystoscopic characteristics
por: Lee, Yu Khun, et al.
Publicado: (2021)

Low-Energy Shock Wave Plus Intravesical Instillation of Botulinum Toxin A for Interstitial Cystitis/Bladder Pain Syndrome: Pathophysiology and Preliminary Result of a Novel Minimally Invasive Treatment
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Clinical application of intravesical botulinum toxin type A for overactive bladder and interstitial cystitis
por: Chen, Jing-Liang, et al.
Publicado: (2020)

Repeated intravesical injections of platelet-rich plasma improve symptoms and alter urinary functional proteins in patients with refractory interstitial cystitis
por: Jiang, Yuan-Hong, et al.
Publicado: (2020)

Comparison of the Clinical Efficacy and Adverse Events between Intravesical Injections of Platelet-Rich Plasma and Botulinum Toxin A for the Treatment of Interstitial Cystitis Refractory to Conventional Treatment
por: Jhang, Jia-Fong, et al.
Publicado: (2023)

Pathophysiology, clinical presentation, and management of ketamine-induced cystitis
por: Jhang, Jia-Fong, et al.
Publicado: (2023)

Multimodal Treatment with Cognitive Behavioral Therapeutic Intervention Plus Bladder Treatment Is More Effective than Monotherapy for Patients with Interstitial Cystitis/Bladder Pain Syndrome—A Randomized Clinical Trial
por: Yu, Wan-Ru, et al.
Publicado: (2022)

Therapeutic Efficacy of Intravesical Platelet-Rich Plasma Injections for Interstitial Cystitis/Bladder Pain Syndrome—A Comparative Study of Different Injection Number, Additives and Concentrations
por: Jiang, Yuan-Hong, et al.
Publicado: (2022)

Decrease of Urinary Nerve Growth Factor but Not Brain-Derived Neurotrophic Factor in Patients with Interstitial Cystitis/Bladder Pain Syndrome Treated with Hyaluronic Acid
por: Jiang, Yuan-Hong, et al.
Publicado: (2014)

Adverse Events of Intravesical OnabotulinumtoxinA Injection between Patients with Overactive Bladder and Interstitial Cystitis—Different Mechanisms of Action of Botox on Bladder Dysfunction?
por: Kuo, Yuh-Chen, et al.
Publicado: (2016)

Bladder Ultrastructure and Urinary Cytokine Abnormality in Patients with Recurrent Urinary Tract Infection and the Changes after Intravesical Platelet-Rich Plasma Injections
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Increased Pro-Inflammatory Cytokines, C-Reactive Protein and Nerve Growth Factor Expressions in Serum of Patients with Interstitial Cystitis/Bladder Pain Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2013)

Smaller bladder capacity and stronger bladder contractility in patients with ketamine cystitis are associated with elevated TRPV1 and TRPV4
por: Yang, Hsueh-Hui, et al.
Publicado: (2021)

O’Leary-Sant Symptom Index Predicts the Treatment Outcome for Onabotulinumtoxin A Injections for Refractory Interstitial Cystitis/Bladder Pain Syndrome
por: Kuo, Yuh-Chen, et al.
Publicado: (2015)

Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Repeated Intravescial OnabotulinumtoxinA Injections Plus Hydrodistention in the Treatment of Interstitial Cystitis/Bladder Pain Syndrome
por: Lee, Cheng-Ling, et al.
Publicado: (2015)

Urinary Oxidative Stress Biomarker Levels Might Be Useful in Identifying Functional Bladder Disorders in Women with Frequency and Urgency Syndrome
por: Jiang, Yuan-Hong, et al.
Publicado: (2023)

Cystoscopic hydrodistention characteristics provide clinical and long-term prognostic features of interstitial cystitis after treatment
por: Yu, Wan-Ru, et al.
Publicado: (2021)

Corrigendum: Improved Urothelial Cell Proliferation, Cytoskeleton and Barrier Function Protein Expression in the Patients With Interstitial Cystitis/Bladder Pain Syndrome After Intravesical Platelet-Rich Plasma Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2022)

Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction
por: Jhang, Jia-Fong, et al.
Publicado: (2018)

Botulinum Toxin A and Lower Urinary Tract Dysfunction: Pathophysiology and Mechanisms of Action
por: Jhang, Jia-Fong, et al.
Publicado: (2016)

Recent advances in recurrent urinary tract infection from pathogenesis and biomarkers to prevention
por: Jhang, Jia-Fong, et al.
Publicado: (2017)

Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection
por: Jhang, Jia-Fong, et al.
Publicado: (2015)

Novel Applications of Non-Invasive Intravesical Botulinum Toxin a Delivery in the Treatment of Functional Bladder Disorders
por: Jhang, Jia-Fong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sgc0f2bdm1peuon3ri3kt9tp09